1. Home
  2. NLSP vs SERA Comparison

NLSP vs SERA Comparison

Compare NLSP & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLSP
  • SERA
  • Stock Information
  • Founded
  • NLSP 2015
  • SERA 2008
  • Country
  • NLSP Switzerland
  • SERA United States
  • Employees
  • NLSP N/A
  • SERA N/A
  • Industry
  • NLSP Biotechnology: Pharmaceutical Preparations
  • SERA Precision Instruments
  • Sector
  • NLSP Health Care
  • SERA Health Care
  • Exchange
  • NLSP Nasdaq
  • SERA Nasdaq
  • Market Cap
  • NLSP 12.4M
  • SERA 70.4M
  • IPO Year
  • NLSP 2021
  • SERA 2021
  • Fundamental
  • Price
  • NLSP $2.50
  • SERA $2.49
  • Analyst Decision
  • NLSP
  • SERA
  • Analyst Count
  • NLSP 0
  • SERA 0
  • Target Price
  • NLSP N/A
  • SERA N/A
  • AVG Volume (30 Days)
  • NLSP 411.8K
  • SERA 806.3K
  • Earning Date
  • NLSP 07-15-2025
  • SERA 08-06-2025
  • Dividend Yield
  • NLSP N/A
  • SERA N/A
  • EPS Growth
  • NLSP N/A
  • SERA N/A
  • EPS
  • NLSP N/A
  • SERA N/A
  • Revenue
  • NLSP N/A
  • SERA $115,000.00
  • Revenue This Year
  • NLSP N/A
  • SERA $390.13
  • Revenue Next Year
  • NLSP N/A
  • SERA $440.54
  • P/E Ratio
  • NLSP N/A
  • SERA N/A
  • Revenue Growth
  • NLSP N/A
  • SERA N/A
  • 52 Week Low
  • NLSP $1.30
  • SERA $1.37
  • 52 Week High
  • NLSP $15.59
  • SERA $9.13
  • Technical
  • Relative Strength Index (RSI)
  • NLSP 52.64
  • SERA 53.89
  • Support Level
  • NLSP $2.16
  • SERA $1.82
  • Resistance Level
  • NLSP $3.08
  • SERA $4.09
  • Average True Range (ATR)
  • NLSP 0.24
  • SERA 0.36
  • MACD
  • NLSP -0.00
  • SERA 0.10
  • Stochastic Oscillator
  • NLSP 30.21
  • SERA 35.74

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: